Zenas Biopharma (ZBIO) vs. Its Peers Critical Analysis

Zenas Biopharma (NASDAQ:ZBIO) is one of 422 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Zenas Biopharma to similar businesses based on the strength of its profitability, valuation, earnings, institutional ownership, analyst recommendations, dividends and risk.

Dividends

Zenas Biopharma pays an annual dividend of $0.05 per share and has a dividend yield of 0.6%. Zenas Biopharma pays out -1.4% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 4.5% and pay out 116.1% of their earnings in the form of a dividend.

Insider & Institutional Ownership

29.3% of shares of all “Biotechnology” companies are held by institutional investors. 22.5% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Zenas Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas Biopharma	N/A	N/A	N/A
Zenas Biopharma Competitors	-14,682.20%	39.10%	-32.41%

Earnings and Valuation

This table compares Zenas Biopharma and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zenas Biopharma	$5.00 million	N/A	-2.37
Zenas Biopharma Competitors	$154.14 million	-$11.26 million	-57.61

Zenas Biopharma’s rivals have higher revenue, but lower earnings than Zenas Biopharma. Zenas Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations and price targets for Zenas Biopharma and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas Biopharma	0	0	2	0	3.00
Zenas Biopharma Competitors	827	2268	4730	56	2.51

Zenas Biopharma currently has a consensus price target of $40.00, indicating a potential upside of 374.50%. As a group, “Biotechnology” companies have a potential upside of 51.75%. Given Zenas Biopharma’s stronger consensus rating and higher probable upside, equities analysts clearly believe Zenas Biopharma is more favorable than its rivals.

Summary

Zenas Biopharma beats its rivals on 7 of the 13 factors compared.

About Zenas Biopharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.